Evicenter
P&T meetings

Tovecimig (CTX-009)

Second-line advanced biliary tract cancer

Also known as ABL001
Last updated
89 sources

Product information and disease descriptionProduct descriptionProduct information

Co-prescribed/Concomitant therapies

5 evidence topics · 3 sources

Paclitaxel as the mandatory combination partner in the second-line setting

“CTX-009 will be administered at 10 mg/kg on Day 1 and Day 15 of every 28-day cycle. Paclitaxel will be administered 80 mg/m2 on Day 1, Day 8 and Day 15 of every 28-day cycle.” (opens the source at this quote in a new tab)

“Paclitaxel was chosen based on the safety and efficacy data from this phase Ib study.” (opens the source at this quote in a new tab)

Antihypertensive therapy

“Uncontrolled hypertension (SBP/DBP >140/90 mmHg) (e.g., patient with SBP/DBP >140/90 mmHg despite the best care including optimizing the anti-hypertensive medication regimen)” (opens the source at this quote in a new tab)

First-line combination with gemcitabine, cisplatin and durvalumab

“In addition, an investigator sponsored trial of tovecimig in the first-line setting in combination with gemcitabine/cisplatin and durvalumab in patients with BTC was initiated in the first quarter of 2025, led by investigators at The University of Texas MD Anderson Cancer Center.” (opens the source at this quote in a new tab)

Combination with immune checkpoint inhibitors: preclinical rationale and development plan

“In this point of view, the results obtained in the current study imply that ABL001 may be another promising partner for combination therapy with immune checkpoint inhibitors, through the facilitation of immune cell infiltration via dual blockade of VEGF and DLL4” (opens the source at this quote in a new tab)

“In addition, we are developing a plan to study the combination of tovecimig with our novel bispecific checkpoint inhibitor, CTX-8371, and with other checkpoint inhibitors.” (opens the source at this quote in a new tab)

Concomitant medication restrictions

“Patients expected to require anticancer treatment other than the investigational product during the clinical study” (opens the source at this quote in a new tab)